سعر ريجليديب 3مجم 30 اقراص 2022

Glimepiride 3 mg oral tablets (sulfonylurea antidiabetic), pack of 30 tablets (3 strips), marketed in Egypt by Sigma.

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; not for type 1 diabetes or diabetic ketoacidosis.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions in clinical trials: hypoglycemia, dizziness, asthenia, headache and nausea.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• History of hypersensitivity to glimepiride or any product ingredient.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• History of allergic reaction to sulfonamide derivatives.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Can cause severe hypoglycemia, which may impair concentration and the ability to drive or operate machinery.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Serious hypersensitivity reactions (anaphylaxis, angioedema, Stevens-Johnson syndrome) have been reported; discontinue if suspected.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• May cause hemolytic anemia, particularly in G6PD deficiency; consider a non-sulfonylurea alternative in such patients.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Drugs increasing glucose-lowering effect (e.g., other antidiabetics, insulin, ACE inhibitors, fluconazole, fibrates, NSAIDs, salicylates, quinolones)May increase hypoglycemia risk; dose adjustment and close monitoring may be needed.DailyMed (U.S. National Library of Medicine)
• Oral miconazolePotential interaction leading to severe hypoglycemia reported.DailyMed (U.S. National Library of Medicine)
• CYP2C9 inhibitors/inducers (e.g., fluconazole, rifampin)Fluconazole may raise and rifampin may lower glimepiride concentrations.DailyMed (U.S. National Library of Medicine)

• Available data have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal outcomes; sulfonylureas cross the placenta and may cause neonatal hypoglycemia, so discontinue at least two weeks before expected delivery.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Unknown whether excreted in human milk; monitor breastfed infants for signs of hypoglycemia.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Glimepiride: Lowers blood glucose mainly by stimulating insulin release from pancreatic beta cells: binds the beta-cell sulfonylurea receptor and closes ATP-sensitive potassium channels (US label section 12.1).